Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial

Diabetes Care

Volumn 37, Issue 5, 2014, Pages 1480-1483

  Perkins, Bruce A ^a   Cherney, David Z I ^a   Partridge, Helen ^a   Soleymanlou, Nima ^b   Tschirhart, Holly ^a   Zinman, Bernard ^a,c   Fagan, Nora M ^d   Kaspers, Stefan ^e   Woerle, Hans Juergen ^e   Broedl, Uli C ^e   Johansen, Odd Erik ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^c MOUNT SINAI HOSPITAL   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; INSULIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEASIBILITY STUDY; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; UPREGULATION; URINARY EXCRETION; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ADULT; ANALYSIS; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE BLOOD LEVEL; MALE; YOUNG ADULT;

ADULT; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; SODIUM-GLUCOSE TRANSPORTER 2; YOUNG ADULT;

EID: 84899105421     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2338     Document Type: Article

References (15)

1. Luippold G, Klein T, Mark M, Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012;14:601-607
2. Mudaliar S, Armstrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care 2012;35:2198-2200
3. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502
4. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose co-transporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14:83-90
5. Cherney DZI, Perkins BA, Soleymanlou N, et al. The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation. 13 December 2013 [Epub ahead of print]
6. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:613-621
7. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375-393
8. Rosenstock J, Jelaska A, Wang F, Kim G, Broedl UC, Woerle HJ; on behalf of the EMPAREG BASAL trial investigators. Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM). Diabetes 2013;62(Suppl. 1):1102-P
9. Wilding JP, Woo V, Soler NG, et al.; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012;156:405-415
10. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2:pii:e001007
11. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61:2199-2204
12. Patrick AW, Hepburn DA, Swainson CP, Frier BM. Changes in renal function during acute insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabet Med 1992;9:150-155
13. Ferrannini EME, Frascerra S, Baldi S, et al. Metabolic response to sodium glucose cotransporter 2 (SGLT2) inhibition with empagliflozin in patients with type 2 diabetes (T2DM). Diabetes 2013;62(Suppl. 1):71-LB.
14. Guo RX, Yang LZ, Li LX, Zhao XP. Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: case-control study and a case report of euglycemic diabetic ketoacidosis in pregnancy. J Obstet Gynaecol Res 2008;34:324-330
15. Burge MR, Hardy KJ, Schade DS. Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. J Clin Endocrinol Metab 1993;76:1192-1198 (Pubitemid 23155435)